Lavender oil 80mg capsules
Available from pharmacies, supermarkets, and retail outlets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Lavender oil
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Lavender oil
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Lavender oil on the MHRA register
Kalms Lavender One-A-Day 80mg capsules
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 9 · Randomised trials: 39 · 2000–2026
Showing the 50 most relevant studies, sorted by most relevant.
H. Ebrahimi, A. Mardani, Mohammad Hasan Basirinezhad, et al.
Explore, 2021
N. Kulakaç, Aylin Aydin Sayilan
Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses, 2023
- Lavandula
- Oils, Volatile
- Plant Oils
Moyano PA, Sheikh ZS, Athar FB, et al.
2026
BackgroundAromatherapy has been proposed as a non-pharmacological adjunctive intervention in critical care settings; however, evidence regarding its effects on objective outcome measures remains inconclusive. This systematic review aimed to evaluate the effectiveness of aromatherapy in modulating objective physiological and biochemical markers in adult intensive care unit (ICU) patients. We hypothesized that the controlled ICU environment would facilitate rigorous measurement of both physiological parameters and biochemical stress markers.MethodsA systematic search was conducted using a novel approach combining lexical database searching (PubMed) and AI-powered semantic search strategies (Elicit, Undermind). Randomized controlled trials examining aromatherapy effects on physiological parameters in critically ill and cardiac patients were included. Outcomes were categorized as cardiovascular, respiratory, and non-cardiovascular/non-respiratory parameters. Subgroup analyses were performed by essential oil type.ResultsEighteen studies comprising 1236 participants were included. Aromatherapy demonstrated moderate effects on cardiovascular parameters (systolic blood pressure: 50% success rate, 5-22 mmHg reductions; diastolic blood pressure: 50%, 3.7-14 mmHg; heart rate: 44%, up to 20 bpm) but limited effects on respiratory parameters (respiratory rate: 25%; peripheral oxygen saturation: 12.5%), with the exception of eucalyptus oil, which showed 75% success for respiratory outcomes in mechanically ventilated patients. Non-cardiovascular/non-respiratory outcomes demonstrated the highest efficacy: anxiety (86%), sleep quality (100%), pain (100%), and sedation outcomes (100%). Subgroup analysis revealed essential oil blends achieved superior cardiovascular and psychological outcomes (100%) compared to lavender alone (64% cardiovascular; 71% anxiety/sedation). Contrary to our hypothesis, no studies measured biochemical stress markers such as cortisol or catecholamines, representing a significant gap in the evidence base. A notable finding was the disparity between evidence certainty: high for anxiety reduction versus low/very low for physiological outcomes, highlighting inadequate control for ICU-specific confounders in existing trials.ConclusionAromatherapy may serve as a safe adjunctive intervention in critically ill patients, with potential cardiovascular benefits requiring cautious interpretation and strong effects on anxiety and sleep outcomes. The absence of biochemical outcome measurements and inadequate control for ICU-specific confounders limits mechanistic understanding and causal inference.
Abstract licence: CC BY
I. Arslan, S. Aydınoğlu, N. B. Karan
European Journal of Pediatrics, 2020
- Lavandula
- Oils, Volatile
- Plant Oils
N. B. Karan
Physiology & behavior, 2019
- Lavandula
- Oils, Volatile
- Plant Oils
I. Crișan, Andreea D. ONA, D. Vârban, et al.
Plants, 2023
Hyun-Ju Kang, Eun Sook Nam, Yongmi Lee, et al.
Asian Nursing Research, 2019
Moneva, Klementina; Medical University of Varna, Doichinova, Maya; Medical University of Varna, Marinov, Trayan; Medical University of Varna, et al.
Medical University of Varna, 2016
Somayeh Zamanifar, Mohammad Iraj Bagheri-Saveh, A. Nezakati, et al.
Journal of Medicine and Life, 2020
Generoso MB, Soares A, Taiar IT, et al.
2017
- Lavandula
- Oils, Volatile
- Plant Oils
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Lavender oil
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72